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Abstract 
Background: Hematopoietic stem cell transplantation is the only curative therapy for 
individuals with sickle cell disease but due to the limited donor pool and complications with 
adult infusions, new methods are in development for applicability to all populations. The 
new method utilizes a treatment regimen developed by John Hopkins with only small trials 
currently being performed. 
Methods: A comprehensive search on the most up to date information was performed with 
MEDLINE, PubMed, MEDLINE-Ovid, EBSCO-Host including all databases, and Web of Science 
with the terms cyclophosphamide or cytoxan, bone marrow transplant(ation) or stem cell, 
and sickle cell. Articles and abstracts generated were screened and analyzed by one 
independent reviewer via inclusion and exclusion criteria and related publication appraised 
in PubMed. Studies were assessed for quality using GRADE criteria. 
Results: Five studies using HLA-haploidentical patient-donor related matches with 
nonmyeloablative techniques have shown promise in decreasing toxicity to patients while 
providing an alternative, curative treatment for individuals who previously did not have that 
option. Nonmyeloablation via John Hopkins protocol with post-transplant cyclophosphamide 
(PTCy) show minimal acute/chronic graft-versus-host disease effects similar to what is seen 
in HLA-matched sibling donors but with decreased stable engraftment.  
Conclusion: A combination of peripheral blood stem cell (PBSC) and bone marrow 
transfusions in haploidentical patients from all trials show stable engraftment with minimal 
cGVHD. Further studies to increase efficacy are needed to modify this conditioning regimen 
with a need for a large randomized control trial with increased TBI and Thiotepa needed to 
support findings presented. 
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Use of Post-Transplant Cyclophosphamide with 
Nonmyeloablative Conditioning in HLA-Haploidentical Stem 
Cell Transplants for Sickle Cell Disease 
Background 
Sickle cell disease (SCD) is genetically induced hemolytic anemia that causes lifelong 
morbidity with vaso-occlusive complications and early mortality in homozygous individuals. 
SCD is prevalent in approximately 1 in every 365 African American births and is predicted to 
increase globally 30% by 2050 with the largest growth in lower to mid socioeconomic status 
countries and population migration in higher SES countries.1 Current estimations of SCD in 
the United States are 100 000.2  
Supportive treatment has been well established with the use of hydroxyurea in 
decreasing mortality in pediatrics but creates a large population of young adults with end 
stage organ damage and other SCD related health concerns.3,4 Common complications of 
SCD include acute chest syndrome, stroke, pulmonary hypertension, and renal failure.5–7 
Presently, the only curative measures available are myeloablative allogenic hematopoietic 
stem cell transplantation (HSCT) from HLA-matched related donors (MRD) which has proven 
efficacious with rates approaching 95% and considered the standard of care in developed 
countries. Alternative disease modifying treatments are needed due to major limitations in 
therapy being only 14% of SCD patients have an MRD overall which is even lower in 
minorities8–10 and the limited therapies available for adults. 
HLA-haploidentical donors conditioning regimen are being established for stem cell 
transplants in SCD, thalassemia’s, and hematologic malignancies to widen the donor pool 
and allow universal access to a therapeutic treatment.6,7,11–13 High dose post-transplant 
cyclophosphamide has been proven to be an integral part of haploidentical transplantation 
to reduce rates of acute and chronic graft vs host disease (GVHD) and transplant related 
mortality (TRM) through immunosuppression via eliminating alloreactive lymphocytes while 
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simultaneously preserving regulatory T cells.6,14,15 To expand treatment to adults, 
advancements in reduced and nonmyeloablative techniques are being utilized due to 
myeloablative therapy increasing mortality and morbidity from SCD complications.12,16 
The studies in this review show promise in the application of peripheral blood and 
bone marrow stem cell transplants in HLA-haploidentical matches employing reduced or 
nonmyeloablative techniques to decrease toxicity to chemotherapy and post-transplant 
cyclophosphamide to expand a known curative treatment to all populations.  
Methods 
A comprehensive search of english written or translated articles on MEDLINE, 
PubMed, MEDLINE-Ovid, EBSCO-Host including all databases, and Web of Science with the 
terms cyclophosphamide or cytoxan, bone marrow transplant(ation) or stem cell, and sickle 
cell. Articles and abstracts generated were screened and analyzed by one independent 
reviewer.  
Eligible studies were nonmyeloablative or reduced intensity/toxicity with post-
transplant cyclophosphamide, HLA-haploidentical donors, patients in all age groups with 
some type of hemoglobinopathy related complication, human trials, and the use of 
peripheral blood stem cell transplant (PBSCT) or bone marrow transplant. Studies excluded 
if utilizing myeloablative regimen, umbilical cord stem cell transplant, HLA-matched sibling 
donor available, and written in the last 6 years due to recent advancements in the field and 
protocol. 
All publications were evaluated via the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) Working Group Guidelines (Table 1).17 
Results 
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After elimination of duplicates, search results yielded 26 different publications since 
2012.  Five of the appraised papers met the criteria (see Table 1). Bolaños et al, 2012,7 at 
John Hopkins University was the first to establish and implement a nonmyeloabalative 
procedure (Figure 1) for HLA-haploidentical and MSD patients. The trial incorporated 19 
individuals with 14 being haploidentical and having a hemoglobinopathy complication and 
followed for a mean period of 711 days after bone marrow infusion. The protocol evolution 
of adding ATG to regimen8, moving from tacrolimus to sirolimus to prevent posterior 
reversible encephalopathy (PRES) and G-CSF primed grafts to increase stable engraftment 
were based off recent research developments and new publishments. No aGVHD or cGVHD 
was observed in all haploidentical patients but 43% had either primary or secondary graft 
rejection (Table 2). The other 53% showed full donor chimerism measured with CD3+ and 
CD34+ levels. The study provides an efficacious regimen for adults and supports the use of 
PTCy in GVHD prophylaxis.7 
Dhedin et al, 2016,18 developed 3 different cohorts and nonmyeloablative 
conditioning regimen with 35 SCD individuals from ages 3-50, all transfused with 
haploidentical related bone marrow based off modified John Hopkins protocol (Figure 1). In 
cohort 1, only 40% of patients had stable engraftment while cohort 2 had the addition of 
thiotepa on D-7 and showed 87.5% stable engraftment with only one aGVHD which was 
managed and cured used corticosteroids (CS). Cohort 3 had 22 patients that underwent 
preconditioning with HU and azathioprine with 18.2% having aGVHD and a mortality of 
13.6% (Table 2). G-CSF primed bone marrow was used in this study as well as all following 
studies. The authors of this multi-institution learning collaboration concluded that the 
addition of thiotepa increases engraftment while preconditioning therapy of HU and 
azathioprine have no summative affect compared to thiotepa alone with minimal toxicity.18 
Fitzhugh et al, 2017,6 was a phase 1/2 clinical trial that split haploidentical 
individuals into 3 cohorts with varying concentrations of PTCy and utilizing PBSC. Cohort 1 
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had a dose of 0mg/kg and ended after 1 out of 3 individuals rejected engraftment. Cohort 2 
dosed 8 individuals 50mg/kg day +3 with 63% engrafting which increased in cohort 3 to 
83% 50mg/kg/d on day +3/+4 to 12 patients. The results showed no TRM and increasing 
rate of chimerism from 0% to 25% to 50% in cohort 3. With 2 days of PTCy, only 1 
individual had both aGVHD and cGVHD (Table 2). In conclusion, the authors report a need 
to integrate other studies involving other hematologic pathology research in developing 
appropriate dosing schemas for SCD and PTCy an integrative part of PBSC transplantation.6 
A recent experimental study by Frangoul et al, 2018,14 used four haploidentical 
patient-donor matches that underwent the same conditioning regimen as one Dhedin et al, 
2016,18 with thiotepa. Patients were 12-23 in age with all 4 having aGVHD grade 2 that was 
resolved with CS. Additionally all 4 had 100% donor chimerism and decreased SCD 
symptomology at the 1-year follow up. The research supports the need for further studies 
with thiotepa because it has manageable toxicities to patients.14 
In a PBSC haploidentical study with 12 participants by Saraf et al, 2018,13 2 patients 
underwent a reduced intensity myeloablation and with both failing to engraft. The protocol 
was modified to incorporate the John Hopkins protocol but with increased TBI on D-1 for the 
following 8 patients ages 30-38 years (Table 2). Approximately 87.5% of patients had 
>95% chimerism post-transplant at the 1-year follow up with 2 episodes of aGVHD grade 
II/IV with 1 of the same individuals having cGVHD who later died from unknown causes. 
Authors discussed that the addition of increased TBI to 3Gy decrease graft rejection in PBSC 
transplants while still maintaining acceptable toxicity for adults.13 
Discussion 
The cumulative data from these five studies6,7,13,14,18 support the necessity of 
expanding alternative methods for stem cell transplantation in sickle cell disease and 
support that nonmyeloablative is a plausible methodology. Additionally, the benefits of PTCy 
-11- 
 
with thiotepa improve engraftment and decrease incidents of GVHD.6,14,18 Historically 
mismatched donors have increased mortality >50% until the establishment of the John 
Hopkins protocol which lay the basis for nonmyeloablative procedures. Following research 
typically revolved around this procedure due to the negligible toxicity and no TRM but the 
high graft rejection rate calls for slight alterations.7 No cytopenia in reduced intensity or 
nonmyeloablative allows it to be a safer method in certain individuals with comorbidities.19 
While myeloablative procedures are currently the method of choice for pediatrics, both can 
cause increased risk of malignancy but alkylating agents more so than radiation thus 
nonmyeloablative may be best in both kids and adults.10,20 
Studies involving non-related donors are in development for SCD with limited 
success of more developing aGVHD grade >2, cGVHD and a TRM of 24% from GVHD.10 
Further studies are required to create safer regimes for individuals who necessitate stem 
cell transplants but have no related donors. 
Conclusion 
In conclusion, nonmyeloablative procedures with PTCy have shown decreased rates 
of both acute and chronic GVHD and increasing levels of stable engraftment. Furthermore, it 
is cost effective and requires minimal cell processing thus can be implemented in countries 
of lower socioeconomic status where SCD rates tend to be the highest.1,21 Advantages of 
alleviating symptoms of a life-threatening disease outweigh the risks of graft failure, 
however unfavorable, if the risk of TRM is minimal at 5.3% when considering quality of life 
and the decreased lifespan of those with SCD. Measures to minimize mortality can be made 
by utilizing bone marrow when possible over PBSC transplant and providing antibiotic and 
vaccinations prophylaxis will further diminish mortality rates.7,22 With only experimental 
research in phase 1/2 trials and taking into account the growing population of patients 
suffering from SCD there is a demand for a large prospective randomized control trial with 
thiotepa, PTCy, and elevated TBI to allow all individuals access to a curative treatment. 
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Table 1: Quality Assessment of Reviewed Articles 
Outcome 
Number 
of 
studies 
Study 
Designs 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
GVHD 5 3 
Experimental 
research, 2 
cohort 
Not 
seriousa,b 
Not serious Seriousc Serious Unlikely Very large 
magnitude 
of effect 
and Dose 
response 
Gradiente 
Very 
Low 
Mortality 5 3 
Experimental 
research, 2 
cohort 
Not 
seriousa 
Not serious Seriousc Serious Unlikely Very Large 
Magnitude 
of Effect 
Very 
Low 
Stable 
engraftment 
5 3 
Experimental 
research, 2 
cohort 
Not 
seriousa,f 
Not serious Seriousc Serious Unlikely Very large 
magnitude 
of effect 
Very 
Low 
a Bolanos et al and Saraf et al had evolutions in protocol.  
b GVHD was graded via NIH guidelines in all studies. 
c Variation in all studies in TBI concentrations and the use of thiotepa in Dhedin et al, 2016, Frangoul et al, 2018 and Saraf 
et al, 2018 affect engraftment and occurrence of GVHD. 
d No confidence intervals were provided due to absolute values and small cohorts. 
e Fitzhugh et al, 2016 conducted a dose response gradient of PTCy in different cohorts. 
f Stable engraftment was measured objectively via CD3+ and CD34+ to determine amount of chimerism. 
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Figure 1. Nonmyeloablative conditioning regimen for stem cell transplantation in SCD 
haploidentical matched patients developed by John Hopkins University7. 
 
 
 
 
